

Glasgow Prognostic Score predicts chemotherapy-triggered acute exacerbation-interstitial lung disease in patients with non-small cell lung cancer

Ryota Kikuchi^a, Hiroyuki Takoi^a, Takao Tsuji^b, Yoko Nagatomo^a, Akane Tanaka^a, Hayato Kinoshita^a, Mariko Ono^a, Mayuko Ishiwari^a, Kazutoshi Toriyama^a, Yuta Kono^a, Yuki Togashi^a, Kazuhiro Yamaguchi^a, Akinobu Yoshimura^c, Shinji Abe^{a,*}

Supplementary Table S1. Frequency of chemotherapy regimens during the clinical course

First line	N	Second line	N	Third line	N	Fourth line	N	Fifth line	N
(n = 56)		(n = 35)		(n = 13)		(n = 4)		(n = 2)	
CBDCA+PTX with/without BEV	29	DOC	19	DOC+RAM	3	DOC	1	S-1	1
CDDP/CBDCA+PEM with/without BEV	15	PEM	8	DOC	2	VNR	1	Nivo	1
CBDCA+Nab-PTX	6	S-1	4	PEM	2	Nab-PTX	1		
CBDCA+S1	3	CBDCA+ PTX	1	Nivo	2	Nivo	1		
CDDP/CBDCA+VNR	2	VNR	1	VNR	1				
CDDP+ETP	1	Nivo	1	Nab-PTX	1				
		Pembrolizumab	1	S-1	1				
				Atezolizumab	1				

N, number; CBDCA, carboplatin; PTX, paclitaxel; BEV, bevacizumab; DOC, docetaxel; RAM, ramucirumab; CDDP, cisplatin; PEM, pemetrexed; VNR, vinorelbine; Nivo, nivolumab; Nab-PTX, nanoparticle albumin-bound paclitaxel; ETP, etoposide.

Supplementary Table S2. Incidence of chemotherapy triggered AE-ILD in each chemotherapy regimen

Chemotherapy	Incidence of AE
Platinum agents (n = 57)	4 (7.0%)
PTX (n = 30)	1 (3.3%)
DOC (n = 25)	8 (32%)
PEM (n = 25)	3 (12%)
S-1 (n = 9)	0 (0%)
Nab-PTX (n = 8)	0 (0%)
VNR (n = 6)	0 (0%)
Others (n = 8)	0 (0%)

AE, acute exacerbation; ILD, interstitial lung disease; PTX, paclitaxel; DOC, docetaxel; PEM, pemetrexed; Nab-PTX, nanoparticle albumin-bound paclitaxel; VNR, vinorelbine; ETP, etoposide. Others: Nivolumab (n = 5), Pembrolizumab (n = 1), Atezolizumab (n = 1), ETP (n = 1)

Supplementary Table S3. Univariate analysis of overall survival in patients who underwent carbon monoxide diffusing capacity (n = 21)

Variable	Univariate analysis		
	HR	95% CI	<i>p</i> value
%predicted DLCO, per %increment	1.016	0.99–1.03	0.155

HR, hazard ratio; CI, Confidence interval; DLCO, carbon monoxide diffusing capacity.

Supplementary Fig. S1. Patient recruitment flow chart. NSCLC, non-small cell lung cancer; ILD, interstitial lung disease; GPS, Glasgow Prognostic Score.

Supplementary Table S1. Frequency of chemotherapy regimens during the clinical course.

Supplementary Table S2. Incidence of chemotherapy triggered AE-ILD in each chemotherapy.

Supplementary Table S3. Univariate analysis of overall survival in patients who underwent carbon monoxide diffusing capacity.